Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;76(2):146-150.
doi: 10.1097/FJC.0000000000000861.

Current Perspectives of Anticoagulation in Patients With COVID-19

Affiliations
Review

Current Perspectives of Anticoagulation in Patients With COVID-19

Elizabeth M Gavioli et al. J Cardiovasc Pharmacol. 2020 Aug.

Abstract

Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in covid-19. Heart. 2020. doi: 10.1136/heartjnl-2020-317056. - DOI
    1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020:e201127. doi: 10.1001/jamaneurol.2020.1127. - DOI
    1. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. doi: 10.1001/jamacardio.2020.0950.
    1. Emanueli C, Badimon L, Marteli F, et al. On behalf of the EU-CardioRNA COST Action (CA17129), Call to action for the cardiovascular side of COVID-19: a call for cooperative action from the EU-CardioRNA COST Action. Eur Heart J. doi: 10.1093/eurheartj/ehaa301.
    1. Zhang T, Sun LX, Feng RE, et al. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E040.

MeSH terms

LinkOut - more resources